Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1050)	6/15/1999 4:27:00 PM
From: dmkst1	Read Replies (1) \| Respond to of 1686

concerning adentri- one place to look may be the CV therapeutic homepage or literature searches. If I remember correctly this is an injectable and most probably would be used for CHF flare-ups which result in hospitalization. there is a firm number of how many of these occur each year but I don't have it here. Probably does not have blockbuster potential like amevive, antova, and later VLA4 inh for diseases beyond asthma. I think it will be awhile until analysts and investors understand the power of a handful of drugs which can modify the immune response at multiple locations. As an aside look at IMNX, has a immune modifier, enbrel, which is really not the most potent drug in the world but because of a favorable side effect profile (I guess it used to be favorable before the label change due to infections etc.) has powered IMNX to a valuation equal to BGEN. When the potential for these drugs is better understood this price will be long gone. maybe these will help in your search cvt.com recap.com have to check for which drug are slated for CHF indication JIMB